Product Overview

HapOnco^® IO Safety NGS Test is a self-developed genetic testing product based on the LIUDUS^® platform for guiding the safe and effective use of immuno-oncology therapy ('IO therapy'). The test can be used on tissue and liquid biopsy to detect predictive biomarkers associated with FDA/NMPA-approved IO and targeted therapies, covering 6 genes positively correlated to IO therapy, 27 genes negatively correlated to IO therapy and 22 genes related to targeted therapy, as well as MSI status determined by our patented algorithm. Thereby, HapOnco^® IO Safety NGS Test assists patients in safely initiating immunotherapy and provides reference information for clinical immunotherapy planning.